Image Source: Unsplash

Getinge AB (GNGBY), headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in hospital, pharmaceutical, and research environs.

The company reports in three segments: acute care therapies (54% of revenue), surgical workflows (32%), and life sciences (14%). Products include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems.

Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales (U.S. 33% of sales), Asia-Pacific 25%, and Europe, Middle East, and Africa the remaining 30%.

Getinge AB (publ) was founded in 1904 in Gothenburg, Sweden.

Three key data points gauge

Getinge AB or any dividend-paying firm.

The key three are:

(1) Price

(2) Dividends

(3) Returns

Those three basic keys best tell whether any company has made, is making, and will make money.

GNGBY Price

Over the past year, Getinge AB share price fell 0.08% from $20.36 to $20.20 as of Monday’s market close.

If Getinge AB shares trade in the range of $16.00 to $26.00 this next year, its recent $20.20 share price might rise to $22.00 by next year. Of course, Getinge’s price could drop about the same $1.80 estimated amount, or more.

My annual upside estimate of $1.80 however, is $0.06 over Getinge’s  average of the past five years upside price momentum.

GNGBY Dividend

Getinge AB has paid variable annual dividends since April, 2013. Getinge’s recent A dividend of $0.42 was declared February 7th 2024 to shareholders of record April 23rd. The payout is coming May 14th.

The forward looking $0.42 annual dividend yields 2.08% at Monday’s $20.20 share price.

GNGBY Returns

To put it all together, add Getinge AB’s estimated annual dividend of $0.42 to the estimated price upside of $1.80 to find a $2.22 gross gain.

At Friday’s $20.20 share price, a little over $1000 would buy 50 shares.

A $10 broker fee (if charged), paid half at purchase and half at sale, would cost us  $0.20 per share.

Subtracting that likely $0.20 brokerage cost from the $2.22 gross gain produces a net gain of $2.02 X 50 shares = $101.00 for a 10% estimated net gain.

You might choose to pounce on Getinge AB. It is a 104 year old dividend paying Swedish medical Instruments and supplies firm.  Furthermore, the estimated $20.80 annual dividend income from $1k invested is just $0.60 over Getinge’s recent $20.20 single share price.

The exact track of Getinge AB’s ongoing future price and dividend will be determined by market action.

Remember the true value of any stock is best realized through personal ownership of shares.

More By This Author:

Current Analysis: Elekta AB (EKTAF)
Current Analysis: Telenor
Current Analysis: SoftBank